摘要
目的比较达格列净与利拉鲁肽对2型糖尿病合并非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)患者的治疗效果。方法随机选取2022年6—11月大庆油田总医院收治的2型糖尿病合并NAFLD患者100例,随机数字法分为达格列净组(A组)和利拉鲁肽组(B组),每组50例,均治疗12周,比较两组患者的临床治疗总有效率、治疗前后相关生化及物理指标。结果两组患者腰臀比(WHR)、体质指数(BMI)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)、血胆固醇(TC)、血三酰甘油(TG)、低密度脂蛋白(LDL-C)、同型半胱氨酸(Hcy)均较治疗前下降,且治疗后B组WHR、BMI低于A组,A组FPG、HbA1c、UA、Hcy、肝脏脂肪含量低于B组,差异有统计学意义(P<0.05);A组治疗总有效率高于B组,差异有统计学意义(P<0.05)。结论对于T2DM合并NAFLD患者,与利拉鲁肽比较,应用达格列净治疗能够更有效的降糖,降低尿酸、同型半胱氨酸、肝脏脂肪含量。
Objective To compare the therapeutic effects of dapagliflozin and liraglutide on type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease(NAFLD).Methods A total of one hundred patients with type 2 diabetes mellitus complicated with NAFLD admitted to Daqing Oilfield General Hospital from June 2022 to November 2022 were randomly selected and divided into dapagliflozin group(group A)and liraglutide group(group B)by random number method,with fifty cases in each group.All patients were treated for 12 weeks.The total effective rate of clinical treatment,and related biochemical and physical indexes before and after treatment were compared between the two groups.Results Patients in the two groups waist to hip ratio(WHR),body mass index(BMI),fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c),insulin resistance index(HOMA-IR),alanine aminotransferase(ALT),aspartate aminotransferase(AST),glutamyl transpeptidase(GGT),blood cholesterol(TC)and blood glycerol triester(TG),low density lipoprotein(LDL-C),blood urea(UA)and homocysteine(Hcy)were all decreased compared with those before treatment,and after treatment,WHR and BMI of group B were significantly decreased compared with group A,FPG,HbA1c,UA,Hcy and the liver fat content of group A was lower than that of group B,and the difference was statistically significant(P<0.05);the total effective rate of group A was higher than that of group B for non-alcoholic liver disease,and the difference was statistically significant(P<0.05).Conclusion For T2DM patients with NAFLD,compared with liraglutide,dapagliflozin treatment can more effectively reduce glucose,uric acid,homocysteine,and liver fat content in patients.
作者
毕婷
于添伟
武丽华
BI Ting;YU Tianwei;WU Lihua(Department of General Practice,Daqing Oilfield General Hospital,Daqing,Heilongjiang Province,163000 China)
出处
《糖尿病新世界》
2023年第8期94-97,共4页
Diabetes New World Magazine
关键词
2型糖尿病
非酒精性脂肪肝
达格列净
肝脏脂肪含量
Type 2 diabetes mellitus
Non-alcoholic fatty liver
Dapagliflozin
Liver fat content
